Articles tagged with Type 1 Diabetes
A study found that adequate vitamin D levels during infancy and childhood are associated with a reduced risk of islet autoimmunity, a precursor to type 1 diabetes. Vitamin D status varies by latitude, and higher childhood levels are significantly linked to decreased risk of IA.
A study published in JAMA found that insulin pump therapy among young patients with type 1 diabetes was associated with lower rates of severe hypoglycemia and diabetic ketoacidosis compared to traditional injections. This innovative treatment approach offers improved clinical outcomes for this vulnerable population.
A new study of children from Sweden and Finland found that the swine flu vaccine Pandemrix did not increase the risk of developing autoantibodies against insulin-producing beta cells or type 1 diabetes. In fact, vaccinated children in Finland showed a reduced risk of developing autoantibodies and type 1 diabetes.
A new trial found that continuous glucose monitoring during pregnancy reduces the number of babies born larger than average, need for intensive care, and pre-eclampsia rates. Birth outcomes improved significantly for mothers using the device compared to traditional finger-prick tests.
A global study of over 800 patients with Type 1 diabetes found that dapagliflozin, a Type 2 diabetes medicine, significantly improved blood sugar levels. The results demonstrate the drug's efficacy as an adjunct therapy to insulin, reducing A1C levels by more than 0.5% without severe hypoglycemia.
Research shows that pregnancy outcomes remain poor for women with type 1 diabetes, especially those diagnosed at a young age. The study found higher rates of pre-eclampsia, stillbirth, and low birth weight among mothers with childhood-onset T1D.
A new biomarker, LRG1, can predict the occurrence of pre-eclampsia in pregnant women with type 1 diabetes, increasing their risk by 4 times. The study found that LRG1 levels were significantly higher in women who developed PE compared to those who did not.
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes. Patients experienced a lower rate of confirmed severe hypoglycemia than observed in patients on placebo and also had weight loss.
Researchers developed a novel antibody detection technology that increases the sensitivity of Type 1 Diabetes tests, enabling screening for more autoimmune antibodies implicated in the disease. The technology holds promise for making populationwide screening practical and catching the disease earlier.
A nationwide Norwegian study found that H1N1 infected individuals, especially children under 15, were twice as likely to develop type 1 diabetes than the general population. Infection with H1N1 influenza virus was linked to a doubled risk of T1D in Norwegians aged 30 or younger.
A new study suggests that specific genetic variants increase the risk of developing type 1 diabetes in later life, including after the age of 30. The research found that individuals with certain HLA genotypes have a higher likelihood of developing late-onset T1D and being diagnosed at an older age.
Regulatory T-cells in adipose tissue increase in response to environmental stimuli, promoting heat production and fatty acid breakdown. This discovery highlights the complex interactions between immune cells and environment in maintaining metabolic balance.
Researchers at Westmead Institute for Medical Research have discovered a new approach to treating type 1 diabetes, using pancreatic islet transplants delivered into the quadriceps muscle. This method presents fewer risks than current clinical practice of transplanting islets into the liver via the portal vein.
Research in mice shows that gut bacteria play a crucial role in modulating the effects of a powerful protective gene against type 1 diabetes. The findings highlight the importance of early environmental exposures to a variety of germs in proper immune system development.
A new study from Karolinska Institutet found that CABG reduces the risk of fatal heart disease and myocardial infarction in patients with type 1 diabetes by 45% and 47% respectively, compared to PCI.
A recent study demonstrates the safety of immunotherapy in treating type 1 diabetes. The treatment showed metabolic effects without accelerating β-cell destruction, suggesting a viable option for patients.
A clinical trial has observed noticeable changes in the behavior of immune systems of type 1 diabetes patients treated with peptides. The treatment has a noticeable effect on the immune system and suggests a potential way to protect remaining beta cells.
Scientists have identified a molecular handle to purify cells destined to become insulin-producing cells, enabling a streamlined and cost-efficient process for generating glucose-responsive beta cells. The discovery aims to address safety and end product consistency challenges in cell therapy for type 1 diabetes.
A new study of adults with Type 1 diabetes for at least 50 years found that better glucose control is associated with a lower risk of cardiovascular disease. The research also discovered that exercise plays a significant role in lowering mortality rates from all causes in this population.
A new study suggests that certain viruses in the intestines may affect a person's chance of developing Type 1 diabetes. Children with less diverse gut viral communities are more likely to generate self-destructive antibodies, while those carrying a specific circovirus group are less likely to develop the disease.
A recent study published in Diabetes Care found that almost half of patients with type 1 diabetes for over ten years still produce some insulin. Higher levels of interleukin-35 were detected in these patients, suggesting a link between this protein and the regeneration of remaining insulin-producing cells.
Recurring gastrointestinal infections in early childhood significantly increase the risk of developing gluten intolerance, according to a new study. The research found a strong association between early respiratory tract infections and an elevated risk of celiac disease.
A new study presents data from an FDA-approved clinical trial testing the generic vaccine BCG to reverse advanced type 1 diabetes. The findings suggest that BCG may induce a permanent increase in expression of genes that restore beneficial regulatory T cells (Tregs) preventing autoimmune attacks on the body's own tissue.
A comprehensive catalog of diseases associated with human leukocyte antigen (HLA) gene variations has been generated by researchers at Vanderbilt University Medical Center. The catalog identifies individuals at risk for certain autoimmune diseases and potential new associations with multiple sclerosis and cervical cancer.
Scientists at the Diabetes Research Institute have successfully transplanted tissue-engineered islet cells into a patient with type 1 diabetes, achieving long-term insulin independence. The omentum tissue site has been found to be a viable alternative for islet implantation, minimizing inflammatory reactions.
Researchers at UT Health San Antonio have developed a gene-transfer technique that increases insulin-producing cells, potentially curing Type 1 and improving Type 2 diabetes. The therapy has cured diabetes in mice without side effects, offering a major advance over traditional insulin therapy.
Researchers discovered genetic influences in 'type 1.5' diabetes that may offer clues for more accurate diagnosis and treatment. The study found that LADA is closer to T1D than T2D, suggesting some patients with adult-onset type 2 diabetes may have late-onset type 1 diabetes.
A pilot study found that a University of Virginia-developed artificial pancreas helped young children with Type 1 diabetes better control their condition. The device automatically monitors and regulates blood-sugar levels, reducing the need for frequent finger pricks and insulin injections.
Researchers analyzed 24,000 retinal exams to develop a new screening schedule for people with type 1 diabetes. The findings suggest that adjusting the frequency of eye screenings based on risk could lead to lower costs and quicker diagnosis and treatment of advanced retinopathy.
The study found that incidence of type 1 diabetes increased by 1.8% annually from 2002 to 2012, while type 2 diabetes rose at a rate of 4.8%. Racial/ethnic minority groups experienced the most significant increases in new diagnosed cases.
A new study finds that an artificial pancreas system improves blood glucose control better than usual home management for children aged 5 to 8 years with type 1 diabetes. The wearable device uses computer algorithms to track blood sugar levels and adjust insulin dosing, resulting in a longer time in the target range.
Research found disparities in type 1 diabetes care among US military children, with white and officers' kids more likely to use insulin pumps and continuous glucose monitors. These technologies led to better glycemic control, but hospitalizations remained similar between pump users and those using multiple daily injections.
A new study found that a videoconferencing educational program equips rural primary care providers with the confidence to manage patients with complex diabetes. The program, called Endo ECHO, improves access to specialized care for large numbers of patients through weekly virtual clinics.
A diet high in short-chain fatty acids produced by gut bacteria has been found to protect against the onset of type 1 diabetes. The study, published in Nature Immunology, suggests that this special diet can improve immune tolerance and reduce inflammation.
A study found that only 65% of youths with type 1 diabetes and 42% of those with type 2 diabetes had undergone an eye examination by six years after initial diagnosis. Groups at reduced likelihood of screening include racial minorities and economically disadvantaged youth.
Researchers at UF Health have found a way to expand and preserve certain cord-blood cells, known as Tregs, which modulate the immune system and prevent autoimmune diseases like Type 1 diabetes. This discovery has important implications for patients with the disease and could potentially be used as a treatment or preventive measure.
The Critical Path Institute has launched a consortium to qualify islet autoimmunity antibodies as prognostic biomarkers for Type 1 Diabetes (T1D) research. The goal is to identify individuals at risk of disease progression and develop interventions to prevent or delay the onset of symptomatic T1D.
A recent study published in the Journal of the American Medical Association found that teens and young adults with type 2 diabetes are at a higher risk of developing kidney, nerve, and eye diseases. This study, funded by NIH and CDC, compared over 1,700 youth with type 1 and 272 youth with type 2 diabetes.
A recent study found that teenagers and young adults with type 2 diabetes are more likely to develop complications, such as diabetic kidney disease, retinopathy, and peripheral neuropathy, compared to those with type 1 diabetes. The study also revealed higher prevalence of hypertension in both groups.
Researchers at Linköping University conducted a pilot study showing promising results in treating type 1 diabetes. The study found stable insulin production in six patients who received GAD-alum injections, with significant improvements in blood sugar levels and reduced need for extra insulin.
The Joslin Diabetes Center is participating in two NIH-funded clinical trials to test artificial pancreas systems that automatically monitor and regulate blood glucose levels. If successful, the trials could lead to regulatory approval for use of these devices, improving glucose control and reducing diabetes self-management burden.
A pivotal trial demonstrated the safety and efficacy of a hybrid closed-loop insulin delivery system in home use, reducing HbA1c levels and preventing severe hypoglycemic events. The system showed significant improvements in glucose control for both adolescents and adults with type 1 diabetes.
Researchers discovered a subpopulation of beta cells that resists immune attack and acquires stemness to persist despite immune attack. This finding may lead to therapies targeting these cells to restore insulin production in type 1 diabetic patients.
The American Diabetes Association has awarded a $1.625-million grant to develop an animal model studying the connection between gut bacteria and autoimmune attack in type 1 diabetes. The research aims to identify mechanisms that may contribute to the disease and potentially lead to treatments that prevent it.
Four NIH-funded research projects aim to test and refine fully automated artificial pancreas systems, replacing traditional methods for managing type 1 diabetes. The studies will evaluate safety, efficacy, user-friendliness, and cost, with the goal of bringing these life-changing devices to those who need them.
A long-term study found that continuous glucose monitoring significantly lowers blood sugar levels in persons with type 1 diabetes, reducing the risk of complications. The treatment also leads to increased well-being and improved treatment satisfaction.
Two studies found that continuous glucose monitoring improved blood sugar levels and reduced hypoglycemia in type 1 diabetes patients using multiple daily insulin injections. The studies showed significant reductions in hemoglobin A1c levels and glycemic variability, with improved treatment satisfaction.
A set of international guidelines helps individuals with type 1 diabetes exercise safely, reducing the risk of hypoglycemia and improving overall health. The guidelines provide recommendations for glucose targets, nutritional and insulin dose adjustments to prevent blood sugar fluctuations during exercise.
A new study reveals that individuals with Type 1 diabetes exhibit distinct gut inflammation and microbiome changes compared to those without diabetes or celiac disease. The research found specific genes associated with gut inflammation and unique combinations of gut bacteria in patients with Type 1 diabetes.
Researchers identified a molecular signaling pathway that promotes sensory neuron growth and prevents or reverses peripheral neuropathy in cell and rodent models of type 1 and 2 diabetes, chemotherapy-induced neuropathy, and HIV. Anti-muscarinic drugs already approved for other conditions may offer new treatment options.
A new study published in Diabetologia suggests that enterovirus infections are associated with the onset of autoimmunity in children who develop type 1 diabetes. The study found a higher incidence of enterovirus infections in children with T1D compared to control children, particularly those who developed islet autoantibodies.
The Human Pancreas Analysis Program (HPAP) aims to study diabetes and pancreatic islets with unparalleled resolution. The program will procure and phenotype pancreatic tissues from individuals with or at risk for Type 1 diabetes.
A study found that type 1 diabetes patients with elevated albumin in their urine had triple the risk of life-threatening kidney and cardiac disease compared to those with normal levels. Copeptin levels were significantly higher in these patients, suggesting a new potential target for therapies.
Researchers at Helmholtz Munich have discovered proteins in the blood that can predict incipient type 1 diabetes, even before symptoms appear. The study identified 41 peptides from 26 proteins that distinguish children with autoantibodies from those without, including proteins associated with lipid metabolism.
Researchers at Wayne State University are developing a new material formulation to resist foreign body reactions in implantable devices, such as insulin infusion pumps. This project aims to improve the long-term use of these devices by reducing the need for replacements.
Scientists at Helmholtz Zentrum München have discovered a mechanism used by the immune system to prepare for attacks on insulin-producing cells in the pancreas. The team identified a signaling pathway triggered by miRNA92a, which leads to an increase in immune cells that promote autoimmunity. Targeted intervention using antagomirs may ...
Aerobic exercise improves glycemic control and reduces insulin requirements in T1D patients. The study found that physically active patients had more responsible behavior in monitoring their glucose levels, suggesting an educational program addressing diet, insulin injecting monitoring, and exercise could be highly advantageous.
A recent study found a connection between follicular T helper cells and the development of type 1 diabetes. The cells were increased in frequency close to disease onset, particularly in children with multiple autoantibodies.
Researchers at the University of Cambridge have developed a new treatment for type 1 diabetes that targets the immune system's damage, aiming to reduce or eliminate daily insulin injections. The treatment uses aldesleukin, a drug that enhances regulatory T cells to prevent autoimmunity.
A recent expert review from the International Osteoporosis Foundation confirms that both type 1 and type 2 diabetes increase the risk of bone fragility. The mechanisms behind this include hyperglycemia, oxidative stress, and microvascular complications, which alter bone turnover and material properties.